McKesson (MCK, Health Care Distributors) Stock Valuation & Fair Value Significantly overvalued
McKesson (MCK, Health Care Distributors) trades at a blended P/E of 21.5, about 41% above its historical normal valuation, with a forward growth estimate of 13.5% and a PEG of 1.60. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 15.3 on the same blended earnings, the 2026-10-02 close of $902.28 corresponds to about $640 a share. This is a valuation reference, not a price target.
- Price $930.25 at the 2026-10-08 close, 4.6% above the 20-day average ($889.07) and 5.5% above the 50-day ($881.83).
- RSI (14) at 62.4.
- 52-week range $723.60 to $993.53: the price is 6.4% below the high and 28.6% above the low.
The Street vs SeerForecast
Wall Street's mean price target for MCK is $979.36 across 14 analysts, 5.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.
Valuation flags
- Overvalued by 41%
Verdict history
tickerseer's rating moved from trading above its usual valuation (2026-06-03) to significantly overvalued (2026-10-05).
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 37 weeks
Frequently asked questions
Is McKesson stock overvalued?
At a blended P/E of 21.5 versus its historical normal P/E of 15.3, McKesson trades about 41% above its typical valuation, with a PEG of 1.60 on 13.5% forward growth. tickerseer currently rates it significantly overvalued.
What is McKesson's fair value and PEG?
McKesson trades at a blended P/E of 21.5 against a historical normal P/E of 15.3, a PEG of 1.60, and a forward growth estimate of 13.5%. Priced at its historical normal P/E of 15.3 on the same blended earnings, the 2026-10-02 close of $902.28 corresponds to about $640 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of McKesson changed?
tickerseer's rating moved from trading above its usual valuation (2026-06-03) to significantly overvalued (2026-10-05).
What is the analyst price target for McKesson?
The mean Wall Street price target for McKesson is $979.36 across 14 analysts, 5.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health Care Distributors. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.